What to Discuss After a Missed or Delayed Dose of Starting Mounjaro at 5 mg
Tirzepatide labeling answers the immediate question directly. A missed weekly injection can be given as soon as possible within four days, or 96 hours. Beyond that window it is skipped, and the next injection lands on the usual day. Doubling up is not part of the instruction. Anything longer than a short lapse is worth raising with the prescriber.
Medically reviewed by Dr. Michael Aziz, MD, Internal Medicine
The two labeled rules, and what they are not
The first rule is the 96-hour window described above. The second governs moving the weekly day: it can be changed if needed, as long as at least three days, or 72 hours, separate two injections. Both rules exist to keep exposure inside the range the weekly schedule was designed around.
Neither rule creates a way to accelerate. Increases still happen in 2.5 mg increments after a minimum of four weeks at the current level, and the sequence still opens at 2.5 mg with 5 mg following after four weeks. A missed injection does not shorten that clock, and taking two injections close together to compensate raises exposure without moving the schedule forward.
Why four days and not seven
Tirzepatide has a half-life of roughly five days, and steady-state plasma concentrations are reached after about four weeks of once-weekly dosing. That long half-life is what makes weekly injection workable, and it is also why a dose taken a day or two late produces little practical difference while a dose taken alongside the next one produces a genuine overlap.
Time to maximum concentration ranges from 8 to 72 hours after a subcutaneous injection, so two doses landing within 72 hours of each other can have peaks that stack. The 72-hour minimum is the label drawing a line under exactly that.
The missed-dose window itself is not provider-specific, but where people read it often is. HealthRX states the 96-hour rule on its Mounjaro page, and manufacturer and telehealth sources such as LillyDirect, Ro, and Henry Meds carry the same instruction. Checking the number against the DailyMed label rather than a single site is the safer habit, since a page that garbles the window can turn a minor lapse into a doubled dose.
What each gap length actually calls for
| Time since the missed injection | What the label directs | Worth raising |
|---|---|---|
| Under 96 hours | Give the dose as soon as possible, then resume the usual weekly day | Nothing, unless it keeps happening |
| More than 96 hours, before the next scheduled day | Skip it; inject on the regular day | Whether the reason was supply, cost, or symptoms |
| A full week or more missed | Not addressed by a simple rule | Whether the current step still fits when treatment resumes |
| Several weeks off the drug | Outside the labeled missed-dose instruction entirely | Whether restarting means returning to an earlier step |
| Moving the weekly day deliberately | Permitted with at least 72 hours between injections | Confirm the new day before changing it |
The part the label leaves to the prescriber
A single skipped week is administratively simple. A month away from the drug is not, because tolerance built during escalation is the thing most likely to have faded. The label records that nausea, vomiting, and diarrhea concentrate during dose escalation and ease with continued treatment, which implies the reverse is worth considering after a long interruption. Whether someone resumes at the level they left or steps back is a judgment made by the prescriber with the record in front of them, and it is not something to work out from the carton.
Two practical items belong in that conversation. Anyone taking oral medications should note that delayed gastric emptying can affect absorption, and the labeled advice about oral contraception attaches to initiation and to each dose escalation, so a restart may pull that advice back into play. Anyone taking insulin or an insulin secretagogue should confirm whether those doses were changed while tirzepatide was paused.
Most missed doses are supply problems, not memory problems
Refill timing, prior authorization, pharmacy stock, and cost are the usual reasons a weekly injection does not happen. Those are worth naming honestly, because the fix differs. A prior authorization lapse is solved by paperwork. A cost problem is solved by a different route or a different product. Neither is solved by changing how the medication is taken.
The route matters here. LillyDirect connects patients to prescribers and ships the branded product. Direct-to-consumer services including Ro, Hims & Hers, LifeMD, WeightWatchers Clinic, and FormBlends manage their own refill cadence, and the question worth asking before a gap happens is how far ahead a reorder ships and what the process is when a shipment is late. A service that reorders on the day the last dose is used will produce missed weeks regardless of anyone’s diligence.
The one response that reliably makes things worse is buying a substitute from an unfamiliar seller to bridge the gap. The FDA maintains guidance on identifying legitimate online pharmacies and has documented counterfeit products entering the supply chain, and a bridging purchase made under time pressure is where that risk concentrates.
Compounded prescriptions do not follow the branded arithmetic
Compounded tirzepatide is not an FDA-approved product, and no reviewed label sets its concentration or its dosing sequence. Strength differs between compounding pharmacies. The 96-hour window and the 72-hour minimum are statements about the approved product, and while the underlying pharmacology is the same molecule, the amount in any given compounded vial is not fixed by anything published.
Reported administration errors involving compounded GLP-1 preparations frequently trace back to someone applying a number from an approved label to a preparation of different strength. After a missed dose, that is precisely the moment when improvising a correction is most tempting and least advisable. The instruction has to come from the prescriber and pharmacy that supplied the vial.
Frequently asked questions
Can two doses be taken to make up for a missed week?
The label does not describe that as an option. It sets a 96-hour window for a late dose and a 72-hour minimum between any two injections, both of which limit overlap rather than permit catch-up. Given a half-life near five days, doubling up raises exposure well past what weekly dosing produces.
Does a missed week undo the previous month?
Not in any mechanical sense, since steady state is reached after roughly four weeks of weekly dosing and one gap does not reset that. What can change is gastrointestinal tolerance, which is why a longer interruption tends to prompt a discussion about which step to resume at rather than an automatic return.
Is it acceptable to shift the injection to a different weekday?
Yes, with a condition. The label permits changing the weekly day provided at least 72 hours separate the two injections involved in the switch. Confirming the plan before making the change avoids the common error of moving the day forward and landing inside that window.
What if a shipment arrives late and the gap was not a choice?
The clinical handling is the same as any other gap, but the cause is worth documenting, because a repeated supply failure is a service problem rather than a treatment problem. Prescribers can often adjust refill timing once they know the pattern rather than the individual incident
